Draft:Franco Kraiselburd
 | Review waiting, please be patient.
This may take 8 weeks or more, since drafts are reviewed in no specific order. There are 2,718 pending submissions waiting for review.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
Reviewer tools
|
Franco Kraiselburd
[edit]Franco Kraiselburd (born c. 2002) is an Argentine-American biomedical engineer, entrepreneur, and inventor recognized for developing advanced regenerative medicine solutions. He is the CEO and co-founder of Asclepii Inc., a healthtech startup based in Cleveland, Ohio, USA. His flagship invention, Artemis, is a low-cost wound healing matrix designed primarily for diabetic patients to prevent amputations and severe infections.[1][2][3]
Early Life and Education
[edit]Kraiselburd was born in Boston, Massachusetts, while his father Santiago Kraiselburd was pursuing a doctorate at Harvard University and his mother was studying at MIT. Growing up, his family lived in several countries including Argentina, Brazil, Chile, Spain, and the United States.[3][4]
Franco began working with stem cells at the age of 12 in São Paulo, Brazil, at the University of São Paulo Medical School laboratory named Nucel. There, he developed an initial wound-healing hydrogel prototype at age 14.[2][5]
Career and Research
[edit]Asclepii Inc.
[edit]In 2022, at age 20, Kraiselburd co-founded Asclepii Inc., with his father and partners, focusing on making regenerative medicine affordable and widely accessible.[2] The company’s name references Asclepius, the Greek god of medicine, reflecting its focus on wound healing and tissue regeneration.[6]
Asclepii raised $2 million in seed funding from Zentynel Frontier Investments, Capital Factory, and other venture capitalists, securing funds to advance product development and commercial launch.[5][7]
Artemis Bandage
[edit]Kraiselburd developed Artemis, a wound dressing designed to help manage healing in a superior manner, particularly in diabetic patients. Artemis works by incorporating a patient’s own blood or stem cells into a collagen-enriched, microporous scaffold. The product aims to bridge the gap between basic wound coverings and costly cellular therapies. Artemis has an estimated production cost significantly lower than existing cellular treatments, making it accessible even in remote areas or resource-constrained settings.[1][5][3][2]
Asclepii has also developed Poseidon, a silver nanoparticle hydrogel to complement Artemis by preparing wounds for optimal healing.[5]
Recognition and Awards
[edit]In November 2024, Kraiselburd was named "Pioneer of the Year" by MIT Technology Review's Innovators Under 35 Latin America.[1][2][8] He was also a finalist in the prestigious SXSW Pitch competition, showcasing Artemis among global startups.[1][9]
Impact and Vision
[edit]Kraiselburd’s vision for Artemis extends beyond medical treatment to broader humanitarian and economic impacts, particularly targeting diabetic foot ulcers, which affect millions globally and lead to high rates of amputations. His work addresses a global healthcare disparity by substantially reducing treatment costs from thousands of dollars per patient to mere dollars.[3][5]
He aims to launch Artemis commercially in the U.S. market around 2025 and expand rapidly into Latin America and other regions thereafter.[5][3]
Personal Life
[edit]Kraiselburd experienced financial hardship, emotional challenges due to his family circumstances, and periods of instability during his youth. He also briefly pursued music as a lead vocalist in a band.[10][1]
He emphasizes authenticity and collaboration as keys to his entrepreneurial and scientific approach.[10]
References
[edit]- ^ a b c d e "Franco Kraiselburd | Innovators Under 35". www.innovatorsunder35.com. Retrieved 2025-09-03.
- ^ a b c d e Stringer, Judy (2024-08-29). "Franco Kraiselburd | 20 In Their 20s 2024". Crain's Cleveland Business. Retrieved 2025-09-03.
- ^ a b c d e Wille, Germán (2024-12-05). "Franco Kraiselburd: el Ingeniero Biomédico de 22 años que fue premiado como Pionero del año por el MIT". LA NACION (in Spanish). Retrieved 2025-09-03.
- ^ "Inspiring Conversations with Franco Kraiselburd of Asclepii". 2023-08-10. Retrieved 2025-09-03.
- ^ a b c d e f admin (2025-04-16). "Rising Star: Scaling HealthTech Ventures: Lessons from Asclepii and the Future of Regenerative Medicine by Franco Kraiselburd from Cleveland, Ohio, United States - CORPORATE INVESTMENT TIMES". Retrieved 2025-09-03.
- ^ "21-year-old CEO seeks to revolutionize wound care industry - Greater Cleveland Partnership". greatercle.com. Retrieved 2025-09-03.
- ^ www.bizjournals.com https://www.bizjournals.com/cleveland/inno/stories/news/2025/03/21/asclepii-vc-funding-wound-care.html?. Retrieved 2025-09-03.
{{cite web}}: Missing or empty|title=(help) - ^ www.eldia.com, Diario El Dia de La Plata. "Diario El Dia de La Plata www.eldia.com". www.eldia.com (in Spanish). Retrieved 2025-09-03.
- ^ "21-year-old CEO seeks to revolutionize wound care industry - Greater Cleveland Partnership". greatercle.com. Retrieved 2025-09-03.
- ^ a b "Inspiring Conversations with Franco Kraiselburd of Asclepii". 2023-08-10. Retrieved 2025-09-03.